Literature DB >> 34470980

Ampelopsin Inhibits Breast Cancer Cell Growth through Mitochondrial Apoptosis Pathway.

Yue Li1,2, Yong Zhou3, Miaoran Wang1, Xiaojing Lin4, Yunqi Zhang4, Irakoze Laurent4, Ying Zhong1, Jibin Li1.   

Abstract

Ampelopsin, a flavonoid with a wide variety of biological activities, has been proposed to be a potent antitumor agent. However, the mechanism by which Ampelopsin shows anti-breast cancer activity remains unclear. Therefore, this study will explore the mechanism of Ampelopsin's anti-breast cancer activity by culturing MDA-MB-231 and MCF-7 breast cancer cells. Cell Counting Kit-8 (CCK-8) method and plate cloning method were used to detect the proliferation inhibition of breast cancer cells. Fluorescence microscopy was used to detect mitochondrial membrane potential (MMP). 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) method was used to determine the content of intracellular reactive oxygen species (ROS). Hoechst 33258 staining was used to detect the apoptotic morphological changes. Transmission electron microscope was used to observe the mitochondrial structure. Western blot was used to detect the protein expression of Bax and Bcl-2. The results showed that Ampelopsin could significantly inhibit the proliferation of breast cancer cells, and promote cells apoptosis. In addition, the occurrence of apoptosis in breast cancer cells was associated with mitochondrial dysfunction, including the loss of mitochondrial membrane potential, the production of large amounts of reactive oxygen species, and the up-regulation of Bax/Bcl-2 expression. In conclusion, Ampelopsin-induced mitochondria damage leads to loss of mitochondria membrane potential, overproduction of ROS and activation of Bax, increasing mitochondria membrane permeability and ultimately inducing breast cell apoptosis. These findings provided a new perspective on the role of Ampelopsin in breast cancer prevention and treatment.

Entities:  

Keywords:  Ampelopsin; breast cancer; mitochondrial apoptosis; proliferation

Mesh:

Substances:

Year:  2021        PMID: 34470980     DOI: 10.1248/bpb.b21-00470

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

1.  Ampelopsin Inhibits Cell Viability and Metastasis in Renal Cell Carcinoma by Negatively Regulating the PI3K/AKT Signaling Pathway.

Authors:  Zhonghe Zhao; Yan Jiang; Zhongguo Liu; Qingyan Li; Tiantian Gao; Shengxia Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-11       Impact factor: 2.629

Review 2.  Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer.

Authors:  Jiajun Wu; Zuowei Xiao; Hongfang Li; Neng Zhu; Jia Gu; Wenmao Wang; Chao Liu; Wei Wang; Li Qin
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

3.  Peroxiredoxin 5 protects HepG2 cells from ethyl β-carboline-3-carboxylate-induced cell death via ROS-dependent MAPK signalling pathways.

Authors:  Dan-Ping Xie; Yi-Xi Gong; Jaihyung Lee; Eui Man Jeong; Chen-Xi Ren; Xiao-Yu Guo; Ying-Hao Han; Yu-Dong Cui; Seung-Jae Lee; Taeho Kwon; Hu-Nan Sun
Journal:  J Cancer       Date:  2022-09-06       Impact factor: 4.478

Review 4.  Strategic developments in the drug delivery of natural product dihydromyricetin: applications, prospects, and challenges.

Authors:  Ruirui Zhang; Hao Zhang; Houyin Shi; Dan Zhang; Zhuo Zhang; Hao Liu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.